TY - JOUR T1 - Deep Neural Survival Networks for Cardiovascular Risk Prediction: The Multi-Ethnic Study of Atherosclerosis (MESA) JF - medRxiv DO - 10.1101/2021.04.12.21255286 SP - 2021.04.12.21255286 AU - Quincy A. Hathaway AU - Naveena Yanamala AU - Matthew J. Budoff AU - Partho P. Sengupta AU - Irfan Zeb Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/15/2021.04.12.21255286.abstract N2 - Background There is growing interest in utilizing machine learning techniques for routine atherosclerotic cardiovascular disease (ASCVD) risk prediction. We investigated whether novel deep learning survival models can augment ASCVD risk prediction over existing statistical and machine learning approaches.Methods 6,814 participants from the Multi-Ethnic Study of Atherosclerosis (MESA) were followed over 16 years to assess incidence of all-cause mortality (mortality) or a composite of major adverse events (MAE). Features were evaluated within the categories of traditional risk factors, inflammatory biomarkers, and imaging markers. Data was split into an internal training/testing (four centers) and external validation (two centers). Both machine learning (COXPH, RSF, and lSVM) and deep learning (nMTLR and DeepSurv) models were evaluated.Results In comparison to the COXPH model, DeepSurv significantly improved ASCVD risk prediction for MAE (AUC: 0.82 vs. 0.79, P≤0.001) and mortality (AUC: 0.86 vs. 0.80, P≤0.001) with traditional risk factors alone. Implementing non-categorical NRI, we noted a 65% increase in correct reclassification compared to the COXPH model for both MAE and mortality (P≤0.05). Assessing the relative risk of participants, DeepSurv was the only learning algorithm to develop a significantly improved risk score criteria, which outcompeted COXPH for both MAE (4.07 vs. 2.66, P≤0.001) and mortality (6.28 vs. 4.67, P=0.014). The addition of inflammatory or imaging biomarkers to traditional risk factors showed minimal/no significant improvement in model prediction.Conclusion DeepSurv can leverage simple office-based clinical features alone to accurately predict ASCVD risk and cardiovascular outcomes, without the need for additional features, such as inflammatory and imaging biomarkers.Competing Interest StatementPartho P. Sengupta is a consultant to Heart Sciences, Ultromics, and Kencor Health. The other authors have nothing to disclose. Funding StatementThis work is supported in part by funds from the National Science Foundation (NSF: #1920920). Including funding from the American Heart Association (AHA-17PRE33660333, to Q.A.H.)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Boards of all MESA field centers, including Wake Forest University School of Medicine, University of Minnesota, Northwestern University, Columbia University, Johns Hopkins University, University of California, and the MESA Coordinating Center for the collection of the original data. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Manuscript Review: ME 535, Deep Neural Survival Networks for Cardiovascular Risk Prediction: The Multi-Ethnic Study of Atherosclerosis (MESA) was reviewed and approved by the MESA P&P Committee and the MESA Steering Committee (SC) providing approval to access data, following registration, and to use the data in the present work. This included access to demographic information, inflammatory panels, cardiovascular imaging data, and cardiovascular functional testing data. MESA and the MESA SHARe project are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support for MESA is provided by contracts N01-HC95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC95166, N01-HC-95167, N01-HC-95168, N01-HC-95169 and CTSA UL1-RR-024156. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesComputations were performed in Python 3.7, all code is provided: https://github.com/qahathaway/MESA. https://github.com/qahathaway/MESA ER -